Chronoscale Holdings Corp quarterly report, Q3 FY2014

Business context and reporting period

Ekso Bionics Holdings, Inc. (formerly PN Med Group, Inc.) filed this unaudited Form 10-Q for the quarter ended December 31, 2013, with nine-month comparisons to December 31, 2012. The statements reflect the pre-merger company, a development-stage shell that had discontinued its planned Chilean medical-supply business and had no revenue. On January 15, 2014, the company completed a reverse merger with Ekso Bionics, Inc., which designs, develops, and commercializes human exoskeletons. Accordingly, the reported 2013 results do not represent the acquired operating business.

Financial results and liquidity

MetricQuarter ended Dec. 31, 2013Quarter ended Dec. 31, 2012Nine months ended Dec. 31, 2013Nine months ended Dec. 31, 2012
Revenue$0$0$0$0
Operating expenses$6,075$1,777$30,762$7,924
Net loss$6,075$1,777$30,762$7,924
Operating cash flowNot separately presentedNot separately presented$(30,642) per cash-flow statement$(11,674)

There was no gross profit or meaningful margin information because the company reported no revenue. The nine-month loss increased by $22,838 year over year; professional fees rose to $26,404 from $7,521, primarily due to OTC-market compliance advisory fees. Basic and diluted loss per share was reported as $(0.00).

At December 31, 2013, cash and total assets were $78, versus $29,175 at March 31, 2013. Current liabilities were $15,789, including $10,869 of unsecured, non-interest-bearing shareholder loans due on demand, $4,170 of accounts payable, and $750 of accrued expenses. Stockholders’ deficit was $15,711, compared with equity of $15,051 at March 31. The company had no reported long-term debt in these pre-merger statements.

Financing cash flow for the nine months was $1,545, all from shareholder loans; the prior-year period received $33,181 from share sales and shareholder loans. The cash-flow statement reports cumulative operating cash use since inception of $42,791 and cumulative financing inflows of $42,869.

Material changes, subsequent events, and outlook

  • The January 2014 reverse merger made Ekso Bionics, Inc. the accounting acquirer. The company also split off its former business and changed its fiscal year-end to December 31.
  • Following the merger, the company raised $30.3 million in aggregate unit sales, including conversion of $5.0 million of bridge notes; $25.3 million was described as PPO proceeds excluding the converted notes. Each unit included one share and a warrant. The filing reports approximately $16.721 million of cash as of February 17, 2014, after transaction expenses of approximately $3.946 million and repayment of Ekso Bionics’ $2.5 million senior note.
  • Management said available resources were expected to fund the plan through mid-2015. It anticipated approximately $9 million in sales and marketing expenses, including regulatory and clinical costs, and approximately $10 million in general and administrative costs over the next two years, with anticipated growth in rehabilitation-hospital product sales. These are expectations, not guarantees.
  • The financing and merger materially increased potential dilution: after the transactions, 78,445,914 shares were outstanding, alongside substantial warrants and 9,886,459 granted options. The 2014 equity plan authorized awards covering up to 14,410,000 shares.

Risks, controls, and contingencies

The filing cites financing availability, long product-development timelines and cash needs, medical-device regulation, clinical-study results, competition, raw-material price volatility, litigation or arbitration, and execution risks. Management stated that no material off-balance-sheet arrangements or known legal proceedings existed. The company had no revenue and very limited working capital at quarter-end; its March 31, 2013 auditor’s report had raised substantial doubt about going concern. A subsequent-event note says the acquired operating company had sufficient capital for the following twelve months.

Management concluded that disclosure controls and procedures were ineffective as of December 31, 2013, citing material weaknesses identified under prior management. New management had begun or planned remediation but had not yet formally evaluated post-merger internal control over financial reporting.

Important facts for investors to verify

  • Reconcile operating cash use: the financial statement reports $(30,642) for the nine months, while MD&A states $(29,497); MD&A also gives a different cumulative operating cash-flow figure than the cash-flow statement.
  • Review the January 2014 merger and financing filings for final proceeds, transaction costs, cash availability, debt repayment, and any conditions or obligations.
  • Assess the acquired exoskeleton business’s operating results, cash burn, regulatory and clinical milestones, and the assumptions behind management’s mid-2015 funding outlook.
  • Evaluate fully diluted capitalization, including warrants, options, anti-dilution provisions, and remaining equity-plan capacity.
  • Track remediation of the disclosed control weaknesses and any future reassessment of internal controls.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.